[go: up one dir, main page]

MX2018002932A - Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer. - Google Patents

Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.

Info

Publication number
MX2018002932A
MX2018002932A MX2018002932A MX2018002932A MX2018002932A MX 2018002932 A MX2018002932 A MX 2018002932A MX 2018002932 A MX2018002932 A MX 2018002932A MX 2018002932 A MX2018002932 A MX 2018002932A MX 2018002932 A MX2018002932 A MX 2018002932A
Authority
MX
Mexico
Prior art keywords
cancer
synthesis
composition
therapeutic agents
compounds
Prior art date
Application number
MX2018002932A
Other languages
English (en)
Inventor
A Kularatne Sumith
Gagare Pravin
H Mayers Carrie
Original Assignee
On Target Laboratories Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by On Target Laboratories Llc filed Critical On Target Laboratories Llc
Publication of MX2018002932A publication Critical patent/MX2018002932A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/006—Palladium compounds
    • C07F15/0066—Palladium compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe nuevos compuestos que son útiles para cirugía guiada por imagen y terapia fotodinámica. En particular los compuestos pueden dirigirse al núcleo o las mitocondrias después de que los compuestos se suministraron a tejidos enfermos tal como cáncer utilizando un ligando que dirige el receptor que se expresa sobre el tejido enfermo y seguido por endocitosis mediada por el receptor y proporciona la actividad efectiva contra las células de cáncer así como otros trastornos. Se describen métodos y composiciones para uso de los mismos.
MX2018002932A 2015-09-09 2016-09-07 Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer. MX2018002932A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562216148P 2015-09-09 2015-09-09
PCT/US2016/050482 WO2017044445A1 (en) 2015-09-09 2016-09-07 Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018002932A true MX2018002932A (es) 2018-09-12

Family

ID=58239886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002932A MX2018002932A (es) 2015-09-09 2016-09-07 Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.

Country Status (10)

Country Link
US (1) US10676487B2 (es)
EP (1) EP3347010A4 (es)
JP (1) JP2018537402A (es)
KR (1) KR20180081494A (es)
CN (1) CN108135885A (es)
AU (1) AU2016318606A1 (es)
CA (1) CA2996307A1 (es)
IL (1) IL257670A (es)
MX (1) MX2018002932A (es)
WO (2) WO2017044443A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
JP7447384B2 (ja) * 2018-06-21 2024-03-12 オスロ ウニヴェルスィテーツスィーケフース ハーエフ 方法
CN111714640B (zh) * 2019-03-14 2023-02-14 北京和益源生物技术有限公司 一种糖修饰的叶酸衍生物制备的纳米运载颗粒及其应用
CN111748002B (zh) * 2019-03-14 2022-03-29 北京和益源生物技术有限公司 一种脱氧葡萄糖修饰的叶酸衍生物及其合成与应用
CN112028898B (zh) * 2019-06-04 2023-06-23 康宏耀源（天津）科技有限公司 不同连接链偶联的叶酸靶向卟吩类光敏剂及其合成和应用
KR102329966B1 (ko) 2020-03-23 2021-11-23 전남대학교산학협력단 양친성 고분자 화합물, 이를 이용한 약물 전달체 및 종양 치료 시스템
WO2025088200A2 (en) * 2023-10-27 2025-05-01 Philochem Ag Acid phosphatase 3 ligands for targeted delivery applications
WO2025092703A1 (zh) * 2023-10-30 2025-05-08 同宜医药（苏州）有限公司 光敏剂偶联体化合物及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
DE60044030D1 (de) 1999-10-08 2010-04-29 Robert C Leif Markerkomplexe aus konjugierten polymeren
WO2004110255A2 (en) 2003-06-09 2004-12-23 Gang Zheng Antineoplastic agents targeted via glut transporters
US9957293B2 (en) 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
WO2008039994A2 (en) 2006-09-28 2008-04-03 The Trustees Of The University Of Pennsylvania Targeted photodynamic therapy agent
JP5690589B2 (ja) * 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 親水性スペーサーリンカーを含有する結合体
CN103298804B (zh) * 2009-04-29 2015-04-29 多异亚德韩国株式会社 二氢卟酚e6-叶酸共轭物、其制备方法以及含有该共轭物的用于癌症治疗的药物组合物
US8940664B2 (en) 2010-11-22 2015-01-27 E I Du Pont De Nemours And Company Oil release with polyethylene oxide segment-containing N-lauroyl amino acid-based compounds
GB201101429D0 (en) * 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
KR101344303B1 (ko) * 2011-10-07 2013-12-24 동성제약주식회사 표적 치료에 관한 종양에 선택성이 있는 콘쥬게이트

Also Published As

Publication number Publication date
WO2017044443A1 (en) 2017-03-16
AU2016318606A1 (en) 2018-04-05
EP3347010A4 (en) 2019-04-10
CA2996307A1 (en) 2017-03-16
EP3347010A1 (en) 2018-07-18
US20170145035A1 (en) 2017-05-25
CN108135885A (zh) 2018-06-08
WO2017044445A1 (en) 2017-03-16
US10676487B2 (en) 2020-06-09
JP2018537402A (ja) 2018-12-20
IL257670A (en) 2018-04-30
KR20180081494A (ko) 2018-07-16

Similar Documents

Publication Publication Date Title
MX2018002932A (es) Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.
MX2025009223A (es) Agentes de union a clec9a y su uso
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2016007351A (es) Terapia de combinacion para tratar cancer.
NZ700759A (en) Combination therapy for treating cancer
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12019501896A1 (en) Therapeutic dendrimers
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EP4299134A3 (en) Fap-activated therapeutic agents, and uses related thereto
MX391720B (es) Terapia combinada para tratar cáncer.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
EP3818991A3 (en) Compositions and methods for treating diseases
MX2020004476A (es) Compuestos piridinicos de pladienolida y metodos de uso.
PH12020500666A1 (en) Pladienolide compounds and their use
TW201613578A (en) Pharmaceutical combinations
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
PH12016502352A1 (en) Pharmaceutical composition
MX2019013862A (es) Terapia de combinacion.
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
NZ604018A (en) Furanyl compounds and the use thereof